Weight-loss drugs developer Kailera surges 62.5% in Nasdaq debut
17/04/2026 18:27
April 17 (Reuters) - Kailera Therapeutics' KLRA.O shares rose 62.5% in their Nasdaq debut on Friday after the weight-loss drug developer raised $625 million in its U.S. initial public offering. (Reporting by Manya Saini in Bengaluru; Editing by Sahal Muhammed) ((Manya.Saini@thomsonreuters.com; X: manya__saini;))
Recent news on Kailera Therapeutics
See all newsChina biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection